New Client? www.DrugScience.org.uk

DRUG SCIENCE

Evidence • Independence • Impact

Constitutional Objects & Governance

Drug Science (Drugscience Ltd) operates under strict Articles of Association, ensuring that all research and educational activities remain independent of political or commercial bias. Our primary objects as a Charitable Company Limited by Guarantee (No. 08032149) are:

01.

Education

Advancing public knowledge in drug harms to prevent suffering.

02.

Advisory

Providing expert advice to practitioners and the public.

03.

Research

Promoting research into the physical and social effects of drugs.

Governance FAQ

Q: How does Drug Science maintain independence from donors?

A: Our Scientific Committee operates independently. All corporate donations are accepted as "Unrestricted Funds" or via specific project grants that do not grant the donor control over research methodology or findings.

Q: Is the charity compliant with Companies House requirements?

A: Yes, as a company limited by guarantee, we file annual audited (or independent examined) accounts and maintain a transparent register of Trustees.

Financial Year Ending June 2024

Total income for the year reached £704,900. Our revenue streams demonstrate a balanced reliance on public generosity and specialized charitable activity fees.

Donations & Legacies £401,620

Charitable Activities £303,280

Total Revenue £704,900

Financial FAQ

Q: What percentage of income goes directly to research?

A: Over 85% of our restricted funding is allocated directly to specific research projects like Project Twenty21 and PAREA.

Q: Are your accounts independently examined?

A: Yes, the 2024 accounts were independently examined by Burgess Hodgson LLP, ensuring full compliance with UK Charity Commission standards.

Project Impact & Evidence

Our impact is defined by data. Through projects like Twenty21, we have built Europe's largest medical cannabis patient registry to inform policy.

Project Twenty21

Gathering real-world evidence on the effectiveness of medical cannabis for chronic pain and anxiety. Funding spent in 2024: £169,049.

PAREA

The Psychedelic Access and Research European Alliance. Bridging the gap between lab research and healthcare access.

Impact FAQ

Q: How does your research affect current UK laws?

A: By providing peer-reviewed evidence to the ACMD and the Home Office, we have directly influenced shifts in medical cannabis scheduling and harm reduction awareness.

ESG Strategic Roadmap 2026

Our roadmap focuses on aligning scientific output with Corporate Social Responsibility (CSR) metrics for potential ESG-focused partners.

1

Platform Optimization

Update WhatImpact and social value profiles with "Public Health Innovation" tags to improve discovery by corporate donors.

2

Social Value Quantization

Develop a metric for "Healthcare Costs Saved" per pound donated to our harm reduction research programs.

Roadmap FAQ

Q: Is Drug Science open to corporate sponsorships?

A: Yes, provided the partnership aligns with our ethical gift policy and does not compromise our scientific independence.

Drug Science (Drugscience Ltd)

Camburgh House, 27 New Dover Road, Canterbury, Kent, CT1 3DN

Registered Charity: 1150449 • Registered Company: 08032149

Corporate & ESG Strategy Document

Drug Science

"Truth, Evidence, and Independence in Drug Science."

Charity No: 1150449

Company No: 08032149

Strategic Review 2026

Executive Summary: The USP

The primary challenge in Drug Science’s corporate fundraising is the perceived stigma of the word "Drug." This strategy repositions our work as evidence-based health innovation and public safety governance.

The Unique Selling Point

Total political and commercial independence. We do not provide "opinions"; we provide the peer-reviewed evidence required for safe social and medical progress.

The ESG Hook

Direct contribution to UN Sustainable Development Goal 3 (Health & Well-being) and Goal 16 (Peace, Justice, & Strong Institutions).

Financial Transparency & Stewardship

Based on the audited results for the year ending 30 June 2024.

Income Performance

In FY2024, the charity achieved a total income of £704,900. Our revenue model is resilient, balanced between unrestricted donations (£401.6k) and project-specific restricted funding (£303.2k), providing a stable foundation for long-term corporate partnerships.

Social Value Matrix

For ESG reporting platforms (WhatImpact/Social Value Portal), we categorize our impact into three pillars:

Pillar	Specific CSR Alignment	Social ROI Indicator
Social (Health)	Mental Health & Wellbeing innovation	Reduced burden on NHS primary care
Social (Equity)	Justice reform & Community safety	Reduction in non-violent drug convictions
Governance	Anti-corruption & Independent research	Informing evidence-based policy regulation

Strategic Roadmap: Corporate Integration

01

Visibility Optimization

Repopulate WhatImpact profiles using "Public Health" and "Scientific R&D" tags. Emphasize the "Safety" and "Education" objects of the charity over "Policy Reform."

02

Network Leveraging

Targeting life sciences and pharmaceutical CSR schemes where our research into medical cannabis (Project T21) and psychedelics (PAREA) provides direct "Social Value" overlap.

03

Reporting Loop

Provide corporate donors with "Impact Summaries" rather than just Annual Accounts. Translate research data into "People Impacted" and "Health Costs Saved."

Corporate Discovery Strategy (SEO/Tags)

Public Health R&D Mental Health Innovation Governance & Integrity Educational Advancement Harm Reduction Social Equity Evidence-Based Policy

Drug Science (Drugscience Ltd) is a charitable company limited by guarantee.

Registered in England and Wales. Registered Office: Camburgh House, 27 New Dover Road, Canterbury, CT1 3DN.

DRUG SCIENCE

Corporate Fundraising & ESG Strategy

Investing in Truth. Advancing Education. Saving Lives.
A roadmap to position Drug Science as the premier ESG partner for unbiased public health research.

⚖️

Unbiased Independence

Founded to keep scientific pursuit free from political and commercial interest. We offer pure, actionable data.

🛡️

Harm Reduction

Mitigating suffering through education and research. We transform drug policy from a criminal issue to a health solution.

🔬

Evidence Base

Generating the gold-standard data (e.g., Project Twenty21) needed to unlock medical innovations and reform.

ESG & Social Value Alignment

How we pitch to Corporate Social Responsibility (CSR) goals.

ENVIRONMENTAL

Safe Disposal & Ecology

Research into Supervised Injection Facilities (SIFs) demonstrates a direct reduction in drug-related litter (needles/paraphernalia) in public spaces, improving urban environments and sanitation.

SOCIAL

Health & Justice Equity

Our core mission. Reducing the burden on the NHS by preventing overdoses. Addressing the mental health crisis through psychedelic research. Reducing social inequality caused by punitive drug laws.

GOVERNANCE

Ethical Leadership

We operate with a Scientific Committee, ensuring rigorous, peer-reviewed outputs. We offer corporates a partner that stands for Integrity and Truth against misinformation.

Financial Transparency

Demonstrating fiscal responsibility and diversified income streams (FY 2024).

To attract corporate donors, we must showcase stability. In 2024, Drug Science reported a total income of £704,900. Crucially, a significant portion comes from independent donations and legacies, proving strong grassroots support, while charitable activities (research grants, educational events) drive the rest.

2024 Income Sources

Source: 30 June 2024 Unaudited Financial Statements

Restricted Fund Activity

Focus on High-Impact Projects: Twenty21 & PAREA

The Multiplier Effect: Social ROI

Why funding Drug Science is a high-yield social investment.

Measuring the SROI of policy change is complex but powerful. Corporate funders need to see that their £1 contributes to systemic savings. By shifting focus from Criminalization to Harm Reduction, we unlock massive societal value.

• ✓
  Healthcare Savings:

  Preventing emergency admissions via education and overdose prevention centres.

• ✓
  Justice Reform:

  Reducing court and incarceration costs for minor drug offences.

• ✓
  Workforce Productivity:

  Innovative treatments (Medical Cannabis, Psychedelics) for chronic pain and PTSD return people to the workforce.

Fundraising & Marketing Roadmap

Phase 1: Brand & USP

Refine the narrative. Move away from "Drug Reform" (political) to "Science-Led Health Solutions" (corporate-safe). Define specific "Funding Products" (e.g., Sponsor a Researcher).

1

2

Phase 2: Platform Optimization

Complete profiles on WhatImpact and similar ESG platforms. Upload "Impact Reports" instead of just annual accounts. Use the tags: Mental Health, Innovation, Education.

Phase 3: Targeted Outreach

Identify corporations with strong "Mental Health" or "Employee Wellbeing" pillars. Pitch Drug Science as the R&D arm of their wellbeing strategy.

3

4

Phase 4: Impact Reporting

Create a feedback loop. Provide quarterly "Science Updates" to corporate partners, showing exactly how their funds advanced specific studies (e.g., Twenty21 data points).

SEO & Tagging Strategy

To be found by ESG algorithms, we must classify our work using high-value, low-stigma keywords.

Public Health Mental Wellbeing Scientific Research Education Harm Reduction Social Justice Innovation Policy Reform Community Safety Medical Cannabis Psychedelic Therapy

SEO Strategy Note:

Avoid "Legalisation" as a primary tag on corporate platforms to minimize risk friction. Use "Policy Reform" or "Evidence-Based Regulation" instead.

Partner with Science. Change the Future.

This strategy document outlines the pathway for Drug Science to secure sustainable corporate funding by leveraging its unique position as an independent scientific body.

© 2026 Strategy Generated for Drug Science. Data sources: 2022-2024 Financial Reports.